Compare Dolby Laboratories, Inc. (DLB) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Viatris Inc — how do they compare? Dolby Laboratories, Inc. trades at $60.91 (market cap $5.82B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 3.2× Dolby Laboratories, Inc.'s market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| DLB | VTRS | |
|---|---|---|
Market Cap | $5.82B | $18.69B |
Sector | Industrials | Health |
52-Week High | $75.62 | $17.86 |
52-Week Low | $48.51 | $9.49 |
Enterprise Value | $5.19B | $30.81B |
Dividend Yield | 2.32% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $61.77, up 1.4% today, with a bullish technical trend and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $0.69 versus $0.67 expected. Revenue remains stable around $1.3 billion annually, with robust gross margins of 87.61%. Recent news highlights growth in Dolby Atmos and automotive licensing, though near-term revenue volatility persists.
DLB offers a compelling valuation with a P/E of 26.29 below the analyst target of $87.50, implying significant upside. Key risks include licensing deal timing and competitive pressures in audio-video tech. Institutional sentiment is positive, with 47% of analysts rating it a Buy, but investors should monitor execution on Q4 growth guidance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
